SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Booker T. Washington — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientBooker T. Washington
Date of birth1856-04-05
IdentifiersMRN HR-NI017-SYN-TD; SSN (made up) 000-17-2284
Document date1915-06-01
AuthorLorraine Whitfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-week check after the losartan increase and dapagliflozin start. [S]

History of Present Illness

Mr. Washington returns three weeks after losartan was increased to 100 mg and dapagliflozin started. His home readings now run in the 140s and 150s over 90s. He has had no headaches for two weeks and palpitations are rare. He passes a little more urine in the daytime since starting dapagliflozin but has had no genital itching, thirst, or lightheadedness on standing. He has taken no pain relievers. On two trips he ate restaurant meals most days and has begun asking for dishes without added salt. [S]

ElementDetail
Home blood pressure140s to 150s over 90s
SymptomsNo headaches for two weeks; palpitations rare
Medication toleranceSlightly more daytime urine; no genital itching, thirst, or lightheadedness
MedicinesEvery dose taken; no NSAIDs or other over-the-counter products
DietAsking for low-salt dishes on the road

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy slightly better; no weight change
CardiovascularNegativeNo chest pain or ankle swelling; palpitations rare
GenitourinaryPositiveSlightly more daytime urine; up twice a night; no genital itching or dysuria
NeurologicalNegativeNo headache or lightheadedness on standing
EyesNegativeReading blur unchanged; no sudden vision change

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1915-05-04activeS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1915-05-04 to 1915-05-11completedS
Losartan 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1915-05-11activeS
Dapagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1915-05-11activeS
Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth dailyOne-half tablet by mouth dailyOral route1915-06-01activeS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1915-05-04activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1915-06-01Body height170cmS
1915-06-01Body weight70kgS
1915-06-01Body mass index (BMI) [Ratio]24.2kg/m2S
1915-06-01Systolic blood pressure148mm[Hg]S
1915-06-01Diastolic blood pressure92mm[Hg]S
1915-06-01Heart rate78/minS
1915-06-01Respiratory rate16/minS
1915-06-01Body temperature36.8CelS
1915-06-01Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1915-06-01Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1915-06-01Potassium [Moles/volume] in Serum or Plasma4.9mmol/L3.5-5.1 mmol/LNormalS
1915-06-01Carbon dioxide, total [Moles/volume] in Serum or Plasma22mmol/L22-29 mmol/LNormalS
1915-06-01Urea nitrogen [Mass/volume] in Serum or Plasma38mg/dL6-24 mg/dLHighS
1915-06-01Creatinine [Mass/volume] in Serum or Plasma2.4mg/dL0.74-1.35 mg/dLHighS
1915-06-01Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M30mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
1915-06-01Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS

Physical Exam

Vital signs recorded on 1915-06-01; see the Vital Signs section. [S]

SystemFinding
GeneralWell
Blood pressure148/92 mmHg, the average of two seated readings after five minutes' rest
HeartRegular rhythm, rate 78; S4
LungsClear
ExtremitiesNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1804 blood pressure of 220/150activeconfirmed I12.9S — Synthetic active diagnosis for the teaching episode; the 1915 findings remain D and the retrospective diagnosis remains R.
Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosisactiveconfirmed N18.32S — Synthetic diagnosis supported by small echogenic kidneys and albuminuria; linked to the documented 1915 diagnosis of Bright's disease.
Hypertensive retinopathy, both eyes, without papilledemaactiveconfirmed H35.033S — Synthetic funduscopic finding that echoes the documented failing vision.
Mild anemia of chronic kidney disease, iron replete; monitoractiveconfirmed D63.1S — Synthetic finding from the baseline hemoglobin and iron studies.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryPotassium and creatinine (basic metabolic panel)2 to 4 weeks after starting or titrating losartan, dapagliflozin, or a diuretic; with each eGFR drawCompleted todayThree weeks after the losartan increase and dapagliflozin start. Potassium 4.9, creatinine 2.4 mg/dL (up 14 percent from baseline), eGFR 30 (down 17 percent), within the 30 percent accepted
LaboratoryPotassium, sodium, and creatinine after starting chlorthalidone2 to 4 weeks after a diuretic startDueChlorthalidone starts today; drawn at the four-week check
LaboratoryeGFR and urine albumin-creatinine ratioAbout 3 times a year for G3b A3DueUrine albumin-creatinine ratio at the four-week check, once the regimen is complete
SurveyKidney failure risk equation, 2 and 5 yearsYearly in G3 to G5DueAt the six-month review (deviation recorded last visit)
ExaminationStandardized office blood pressureEvery visit; target systolic below 120 when toleratedCompleted today148/92 mmHg
ExaminationWeight, BMI, and cardiac auscultationEvery visitCompleted today70 kg; S4
Medication safetyDapagliflozin toleranceEach visit while startingCompleted todayNo genital infection, volume depletion, or lightheadedness
Medication safetyMedication review: NSAID avoidance and kidney dosingEvery visitCompleted todayNo NSAIDs; doses checked for eGFR 30
Self-managementHome blood pressure log, sodium below 2 g a day, and activityEvery visitCompleted todayHome log reviewed; low-salt choices on the road

Goal progress:

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026)

Follow-up: Four-week check with potassium, sodium, creatinine, and a urine albumin-creatinine ratio after starting chlorthalidone. Next scheduled visit 1915-06-29: four-week check after adding chlorthalidone. [S]